Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASO by Umme Sabrina Haque, Melissa Kohut, Toshifumi Yokota

Subjects: Get full text

Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases by Ashok Verma

Subjects: Get full text

Therapeutic targeting of alternative splicing by Jarosław Paluszczak

Subjects: Get full text

Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy by Harry Wilton-Clark, Toshifumi Yokota

Subjects: “…eteplirsen…”
Get full text

Adverse events associated with eteplirsen: A disproportionality analysis using the 2016–2023 FAERS data by Zhicheng Dai, Guangming Wang, Jiafeng Zhang, Qinghua Zhao, Lei Jiang

Subjects: “…Eteplirsen…”
Get full text

Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA by Joel Iff, Yi Zhon, Edward Tuttle, Deepshekhar Gupta, Xander Paul, Erik Henricson

Subjects:

Eteplirsen in the treatment of Duchenne muscular dystrophy by Lim KRQ, Maruyama R, Yokota T

Subjects: Get full text

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis by Yuko Shimizu-Motohashi, Terumi Murakami, En Kimura, Hirofumi Komaki, Norio Watanabe

Subjects: “…Eteplirsen…”
Get full text